A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single and Multiple Doses of ENC1018 in Healthy Adult Subjects
Latest Information Update: 30 Apr 2025
At a glance
- Drugs ENC 1018 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors EnnovaBio
Most Recent Events
- 25 Apr 2025 Status changed from not yet recruiting to completed.
- 01 Feb 2024 New trial record